Continuous Infusion of Coagulation Products in Hemophilia

Angelika Batorova; Uri Martinowitz

doi:10.1002/9781444318555.ch6

Continuous Infusion of Coagulation Products in Hemophilia

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Original language	English
Title of host publication	Textbook of Hemophilia
Subtitle of host publication	Second Edition
Publisher	Wiley-Blackwell
Pages	44-51
Number of pages	8
ISBN (Print)	9781405169141
DOIs	https://doi.org/10.1002/9781444318555.ch6
State	Published - 13 Aug 2010
Externally published	Yes

Keywords

Area under the curve (AUC), total amount of FVIII required
Bacteriologic safety of continuous infusion
Coagulation product continuous infusion in hemophilia
Continuous administration of coagulation factors - and pharmacokinetic elimination
Continuous infusion (CI) of recombinant FVIII in hemophilia A
Continuous infusion technique and concentrate stability
Modern methods of hemophilia treatment - requirements for quality of products
Modes of continuous infusion and treatment protocols
Pharmacokinetic evaluation, prior to planned CI - not mandatory
Thrombophlebitis, site of venous access - adverse event of CI of undiluted FVIII concentrates

Access to Document

10.1002/9781444318555.ch6

Cite this

@inbook{90da2994ac254437894a39d075482c84,

title = "Continuous Infusion of Coagulation Products in Hemophilia",

keywords = "Area under the curve (AUC), total amount of FVIII required, Bacteriologic safety of continuous infusion, Coagulation product continuous infusion in hemophilia, Continuous administration of coagulation factors - and pharmacokinetic elimination, Continuous infusion (CI) of recombinant FVIII in hemophilia A, Continuous infusion technique and concentrate stability, Modern methods of hemophilia treatment - requirements for quality of products, Modes of continuous infusion and treatment protocols, Pharmacokinetic evaluation, prior to planned CI - not mandatory, Thrombophlebitis, site of venous access - adverse event of CI of undiluted FVIII concentrates",

author = "Angelika Batorova and Uri Martinowitz",

year = "2010",

month = aug,

day = "13",

doi = "10.1002/9781444318555.ch6",

language = "אנגלית",

isbn = "9781405169141",

pages = "44--51",

booktitle = "Textbook of Hemophilia",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Continuous Infusion of Coagulation Products in Hemophilia

AU - Batorova, Angelika

AU - Martinowitz, Uri

PY - 2010/8/13

Y1 - 2010/8/13

KW - Area under the curve (AUC), total amount of FVIII required

KW - Bacteriologic safety of continuous infusion

KW - Coagulation product continuous infusion in hemophilia

KW - Continuous administration of coagulation factors - and pharmacokinetic elimination

KW - Continuous infusion (CI) of recombinant FVIII in hemophilia A

KW - Continuous infusion technique and concentrate stability

KW - Modern methods of hemophilia treatment - requirements for quality of products

KW - Modes of continuous infusion and treatment protocols

KW - Pharmacokinetic evaluation, prior to planned CI - not mandatory

KW - Thrombophlebitis, site of venous access - adverse event of CI of undiluted FVIII concentrates

UR - http://www.scopus.com/inward/record.url?scp=84885773492&partnerID=8YFLogxK

U2 - 10.1002/9781444318555.ch6

DO - 10.1002/9781444318555.ch6

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:84885773492

SN - 9781405169141

SP - 44

EP - 51

BT - Textbook of Hemophilia

PB - Wiley-Blackwell

ER -

Continuous Infusion of Coagulation Products in Hemophilia

Keywords

Access to Document

Other files and links

Cite this